Executive Profiles

Eric Dube, one of this years Pharm Exec Emerging Pharma Leaders, is not yet 40 and is now GSK's senior VP of strategy after already holding seven "very different" roles at the company.

It's good to look to other industries such as FMCG - and to products such as Pepsi and Horlicks - for lessons in emerging market success, writes Nick Stephens.

Eli Lilly CEO John Lechleiter on his agenda as incoming chairman of PhRMA, US healthcare reform, the euro crisis, and the small problem, of innovation.

Broaden your industry exposure. Think beyond yourself... Timely advice from this year's HBA Woman of the Year, Carolyn Buck Luce.

Throughout her life, HBA Woman of the Year Carolyn Buck-Luce has made progress by recognizing that when one door closes, another one opens.

India's most prominent scientist, Dr R.A. Mashelkar, President of the Global Research Alliance, on delivering medicines profitably but cheaply to low income countries.

Pharm Exec speaks to Bausch + Lomb CEO Brent Saunders about how he turned around "a very troubled company".

Mason Tenaglia offers empirical defense of coupons and copay offset programs.

It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle?

Pharm Exec sits down with CEO Atsushi Nagahisa to explore how culture can maximize the value of an inherited portfolio

Keeping skittish patients on their medicines ought to be a strategic priority for Big Pharma - but is it? Pharm Exec convenes an expert round table to examine how best to make progress and agree on some practical steps for incorporation in the campaign agenda.

Fred Frank, Vice Chairman, P.J. Solomon Co.

Pharm Exec sits down with Steve Collis, CEO of AmerisourceBergen to discuss his agenda for retooling the drug distribution giant.

Josef von Rickenbach, President & CEO, Parexel

Can cooperative ties between Big Pharma, NGOs, government, and international organizations pay the freight in making the fight against neglected diseases a permanent fix in global health?

A Q&A with Kristin Peck, the drugmaker's Executive Vice President, Worldwide Business Development and Innovation.

A Q&A with Andrew Webber, President and CEO of the National Business Coalition on Health

Taking Onyx Pharmaceuticals to new heights – CEO Tony Coles talks to PharmExec about the midsize company's transition from adolescence to adulthood.

Successful negotiations require a willingness to take risks and an ability to adapt

According to Eli Lilly, managing alliances requires more than good people skills

The determination of Pfizer's Freda Lewis-Hall has enabled her to find a ray of hope in every situation she's encountered

Can PhRMA's own business model synch with industry's Pharm Exec takes a closer look at PhRMA's new leadership.

Once occupied by a single pharma leader, the roles of CEO, president, and board chairman are increasingly being separated. What's behind the trend?

Pfizer's Specialty Product Business Unit leader discusses his vision for the drug giant's specialty business; now the largest in the industry.

As head of GSK's North American pharma, Deirdre Connelly has the daunting challenge of trying to turn around the sluggish US market. If she succeeds, Connelly may find herself auditioning as the first female Big Pharma CEO.

The economy is turning around; leaders need to position their companies now for the market bounce.

Leaders manage their time and focus their resources by limiting unwanted interruptions.

An open letter to Rep. Henry Waxman (D-CA)

Business schools must prepare students for the post-recession economy, not teach them principles applicable to 2003.

Too many people think of creativity as a mystic flash of inspiration. It's also hard work that needs to be built into every leader's professional life.